

[illegible]

ing t
ids o
ing t
ompo
oster
meth
one,
lone,
pharm
hereo
ing t
eases
epend
en de
A (Ec
binoi
ck")
ion u
ical
sease

ing to
compou
oster
meth
one,
lone,
pharm
hereo
ing t
eases
epend
en de
A (Ec
binoi
ck")
ion u
ical
sease

ing t
eases
epend
en de
A (Ec
binoi
ck")
ion u
ical
sease

ical
sease

addictive drug responsible for the addictive disease, the pharmacodynamic equivalent thereof or another addictive drug or the pharmacodynamic equivalent thereof (particularly of an opioid) and at least one agonist of the corticosteroid and/or mineralo-corticosteroid receptors, particularly a corticosteroid.

6. Pharmaceutical composition according to claim 5 which contains the addictive drug or the pharmacodynamic equivalent thereof in a high dosis, i.e. on the threshold of undesired side effects hazardous to health and at least one corticosteroid in the amount of 0.5-100 mg/day as the maintenance dosage and a 2 to 10 times higher amount for the initial dosage for a patient having a body weight of 60-80 kg.

7. Method for the treatment of addictive diseases by administration of at least one agonist of the corticosteroid and/or mineralo-corticosteroid receptors, particularly a corticosteroid and an addictive drug or the pharmacodynamic equivalent thereof, wherein an addict is administered a combination of agonists of the corticosteroid and/or mineralo-corticosteroid receptors, particularly corticosteroid and addictive drug or the pharmacodynamic equivalent thereof.

8. Method according to claim 7, wherein prior to the combined application, a preparing treatment with at least one corticosteroid is carried out.

9. Method according to claim 7, wherein after the application of the combination of corticosteroid and addictive drug or the

09854817.050901

A1

pharmacodynamic equivalent thereof, an addictive drug
or the pharmacodynamic equivalent thereof is
administered.

10. Method according to claim 7, wherein
after the combined application a follow-up treatment
with a forced application of an addictive drug or the
pharmacodynamic equivalent thereof is carried out.

A1

add A2
add B3

09851817-050901